Six-year-old biotech startup MegaRobo Technologies has raised about $300 million from investors including an arm of Goldman Sachs Group Inc., securing one of the year’s largest Chinese venture capital investments despite a global tech sector rout.
To read the entire story, you must be logged in.
Please log in now or register with us.
